Literature DB >> 7768671

In vitro inhibition of murine IFN gamma production by phosphorothioate deoxyguanosine oligomers.

M D Halpern1, D S Pisetsky.   

Abstract

Phosphorothioate (PT) oligonucleotides are designed as specific agents for antisense therapy although they have been reported to exert non-specific immunomodulatory effects. To elucidate further their actions, the effect of PT deoxyguanosine oligomers (S-oligo(dG)) on in vitro cytokine production by mouse splenocytes was studied. S-oligo(dG)20 inhibited production of INF gamma induced by Con A, E. coli DNA or the combination of PMA and calcium ionophore A23187. The diester analogue was inactive, and of PT homo-oligomers tested, S-oligo(dG)20 was the most active. PT compounds with as few as 5 dG residues could also block INF gamma production. These results indicate that base composition and length, as well as the PT backbone, contribute to the inhibition of INF gamma production and extend the range of immunomodulatory effects of PT compounds.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7768671     DOI: 10.1016/0162-3109(95)00043-s

Source DB:  PubMed          Journal:  Immunopharmacology        ISSN: 0162-3109


  16 in total

Review 1.  Mechanisms of immune stimulation by bacterial DNA.

Authors:  D S Pisetsky
Journal:  Springer Semin Immunopathol       Date:  2000

Review 2.  Nucleic acid sensing receptors in systemic lupus erythematosus: development of novel DNA- and/or RNA-like analogues for treating lupus.

Authors:  P Lenert
Journal:  Clin Exp Immunol       Date:  2010-05-07       Impact factor: 4.330

3.  Inhibition of a C-rich oligodeoxynucleotide on activation of immune cells in vitro and enhancement of antibody response in mice.

Authors:  Guang Yang; Min Wan; Yongsheng Zhang; Luguo Sun; Ran Sun; Dali Hu; Xiaojing Zhou; Li Wang; Xiuli Wu; Liying Wang; Yongli Yu
Journal:  Immunology       Date:  2010-12       Impact factor: 7.397

Review 4.  Synthetic oligonucleotides as modulators of inflammation.

Authors:  Dennis Klinman; Hidekazu Shirota; Debra Tross; Takashi Sato; Sven Klaschik
Journal:  J Leukoc Biol       Date:  2008-04-22       Impact factor: 4.962

5.  Suppression of immune responses by nonimmunogenic oligodeoxynucleotides with high affinity for high-mobility group box proteins (HMGBs).

Authors:  Hideyuki Yanai; Shiho Chiba; Tatsuma Ban; Yukana Nakaima; Takashi Onoe; Kenya Honda; Hideki Ohdan; Tadatsugu Taniguchi
Journal:  Proc Natl Acad Sci U S A       Date:  2011-06-27       Impact factor: 11.205

Review 6.  Inhibitory oligodeoxynucleotides - therapeutic promise for systemic autoimmune diseases?

Authors:  P Lenert
Journal:  Clin Exp Immunol       Date:  2005-04       Impact factor: 4.330

7.  The arthritogenic and immunostimulatory properties of phosphorothioate oligodeoxynucleotides rely on synergy between the activities of the nuclease-resistant backbone and CpG motifs.

Authors:  Jan L Bjersing; Kristina Eriksson; Andrej Tarkowski; L Vincent Collins
Journal:  Inflammation       Date:  2004-02       Impact factor: 4.092

Review 8.  Classification, mechanisms of action, and therapeutic applications of inhibitory oligonucleotides for Toll-like receptors (TLR) 7 and 9.

Authors:  Petar S Lenert
Journal:  Mediators Inflamm       Date:  2010-05-18       Impact factor: 4.711

9.  Characterization of suppressive oligodeoxynucleotides that inhibit Toll-like receptor-9-mediated activation of innate immunity.

Authors:  Mirjam Peter; Konrad Bode; Grayson B Lipford; Florian Eberle; Klaus Heeg; Alexander H Dalpke
Journal:  Immunology       Date:  2007-10-23       Impact factor: 7.397

10.  DNA-like class R inhibitory oligonucleotides (INH-ODNs) preferentially block autoantigen-induced B-cell and dendritic cell activation in vitro and autoantibody production in lupus-prone MRL-Fas(lpr/lpr) mice in vivo.

Authors:  Petar Lenert; Kei Yasuda; Liliana Busconi; Patrice Nelson; Courtney Fleenor; Radhika S Ratnabalasuriar; Peter L Nagy; Robert F Ashman; Ian R Rifkin; Ann Marshak-Rothstein
Journal:  Arthritis Res Ther       Date:  2009-05-28       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.